{"id":286,"date":"2023-02-13T16:30:00","date_gmt":"2023-02-13T08:30:00","guid":{"rendered":"https:\/\/metabiopharma.com\/?p=286"},"modified":"2024-03-20T15:08:00","modified_gmt":"2024-03-20T07:08:00","slug":"mo","status":"publish","type":"post","link":"http:\/\/en.metabiopharma.com\/index.php\/2023\/02\/13\/mo\/","title":{"rendered":"Dr. \u00a0Anjin Xianyu, Co-founder and CTO of META Pharmaceuticals, was honored to be listed in the Shenzhen U30 Young Entrepreneurs List of “Science and Innovation China”.\ufffc"},"content":{"rendered":"\n

In 2021<\/strong>, under the guidance of the China Association for Science and Technology (CAST)<\/strong>, the Science and Technology Communication Center of CAST<\/strong>\u00a0and the Shenzhen Association for Science and Technology (SZAST)<\/strong>\u00a0initiated the selection of the first \u201cScience and Innovation in China<\/strong>\u201d Youth Entrepreneurship List\u2014Shenzhen U30 Youth Innovation and Entrepreneurship Activity<\/strong>. This initiative focuses on high-tech fields such as artificial intelligence<\/strong>, chip design<\/strong>, biomedicine<\/strong>, big data<\/strong>, advanced manufacturing<\/strong>, energy-saving and environmental protection<\/strong>, and new materials<\/strong>, among others.<\/p>\n\n\n\n

In 2022<\/strong>, following the Shenzhen U30 selection work program, 30 outstanding young technology entrepreneurs<\/strong>\u00a0were ultimately chosen. The selection process involved recommendations from various community sectors, preliminary project assessments, expert evaluations, and the collection of opinions. Dr. Anjin Xianyu<\/strong>, co-founder and CTO of META Pharmaceuticals<\/strong>, was honored to be included in this prestigious list.<\/p>\n\n\n\n

\"\"
Dr. Anjin Xianyu, Co-Founder and CTO of META Pharmaceuticals<\/figcaption><\/figure><\/div>\n\n\n\n

Dr. Anjin Xianyu<\/strong>, a co-founder and CTO of META Pharmaceuticals<\/strong>, plays a pivotal role in the company\u2019s growth. His responsibilities span the development of META\u2019s proprietary AI-assisted metabolism and pathway drug target discovery platform. By synergizing artificial intelligence with experimental biology, Dr. Xianyu drives innovation in the field. His expertise lies in creating computational models for metabolic targets, ensuring that META remains at the forefront of cutting-edge science and technology.<\/p>\n\n\n\n

“Shenzhen U30 Young Entrepreneurs in “Science and Innovation China<\/p>\n\n\n\n

In no particular order<\/p>\n\n\n\n

\"\"<\/figure><\/div>\n\n\n\n
\"\"
About Meta<\/figcaption><\/figure><\/div>\n\n\n\n

META Pharmaceuticals<\/strong>\u00a0is the first commercialization company in China to deeply cultivate<\/strong>\u00a0in the emerging field of immune metabolism<\/strong>, with a focus on developing first-in-class original drugs<\/strong>. The founding team primarily hails from top research hospitals in the U.S., including Cornell University Medical College<\/strong>\u00a0and Memorial Sloan Kettering Cancer Center<\/strong>\u00a0in New York City. In June of 2022<\/strong>, META Pharmaceuticals successfully completed its Seed and Pre-A rounds of financing<\/strong>, totaling hundreds of millions of RMB. This significant milestone was led by Forcefield Ventures<\/strong>, XtalPi Inc.<\/strong>, IMO Ventures<\/strong>, and Tiantu Capital<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"

In 2021, under the guidance of the China Association fo […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[],"_links":{"self":[{"href":"http:\/\/en.metabiopharma.com\/index.php\/wp-json\/wp\/v2\/posts\/286"}],"collection":[{"href":"http:\/\/en.metabiopharma.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/en.metabiopharma.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/en.metabiopharma.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/en.metabiopharma.com\/index.php\/wp-json\/wp\/v2\/comments?post=286"}],"version-history":[{"count":4,"href":"http:\/\/en.metabiopharma.com\/index.php\/wp-json\/wp\/v2\/posts\/286\/revisions"}],"predecessor-version":[{"id":396,"href":"http:\/\/en.metabiopharma.com\/index.php\/wp-json\/wp\/v2\/posts\/286\/revisions\/396"}],"wp:attachment":[{"href":"http:\/\/en.metabiopharma.com\/index.php\/wp-json\/wp\/v2\/media?parent=286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/en.metabiopharma.com\/index.php\/wp-json\/wp\/v2\/categories?post=286"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/en.metabiopharma.com\/index.php\/wp-json\/wp\/v2\/tags?post=286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}